Jul 15, 2026 · 6 min · 6 segments
In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new…
Manojkumar BupathiGuestSummer JohnsonHostTo start off, from a community practice perspective, what did it take for your team to be prepared to administer this therapy?
From a community practice standpoint, we had a slight advantage over a lot of other places when we're thinking about using n-portimapidotin and pembrolizumab.
We were involved in the early phase clinical trials that utilize these two regimens.
So we had the advantage of learning the toxicity relating to these drugs as the drugs were actually being developed.
So it made it a little bit easier for us to adopt the use of these drugs.
The challenge was more of how do you integrate the regimen into your treatment paradigm.
To start off, from a community practice perspective, what did it take for your team to be prepared to administer this therapy?
From a community practice standpoint, we had a slight advantage over a lot of other places when we're thinking about using n-portimapidotin and pembrolizumab.
We were involved in the early phase clinical trials that utilize these two regimens.
So we had the advantage of learning the toxicity relating to these drugs as the drugs were actually being developed.
So it made it a little bit easier for us to adopt the use of these drugs.
The challenge was more of how do you integrate the regimen into your treatment paradigm.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
